← back to search

Shahin Lockman

Harvard University · US
Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment, HIV Research and Treatment, and HIV-related health complications and treatments.
h-index
52
citations
13,123
works
350
NIH funding
primary concept
Medicine
email

Recent publications

Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIV.
2026cited by 0position: contributordoi
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study.
2026cited by 0position: contributordoi
Long-Acting Antiretroviral Therapy for Breastfeeding Women With HIV Experiencing Barriers to Adherence in Zimbabwe: Modeling Clinical Impact and Cost-effectiveness.
2026cited by 0position: contributordoi
High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana.
2025cited by 3position: contributordoi
Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy.
2025cited by 2position: contributordoi
Comparison of central obesity prevalence among adults living with and without HIV in Botswana: a cross-sectional study
BMJ Open 2025cited by 1position: middledoi
Brief Report: Predictors of Concurrent Sexual Partnerships and Association With Recent HIV Infection in a Large Population-Based Survey in Botswana.
2025cited by 1position: contributordoi
High prevalence of albuminuria among adult males living with HIV in Botswana
Scientific Reports 2024cited by 4position: middledoi
Self-reported cardiovascular disease risk factor screening among people living with HIV vs. members of the general population in Botswana: a community-based study
BMC Public Health 2024cited by 4position: middledoi
Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana.
2024cited by 3position: contributordoi
Low Prevalence of Nirmatrelvir-Ritonavir Resistance-Associated Mutations in SARS-CoV-2 Lineages From Botswana.
2024cited by 2position: contributordoi
Emergence of Omicron FN.1 a descendent of BQ.1.1 in Botswana.
2024cited by 2position: contributordoi
Rapid dynamic changes of FL.2 variant: A case report of COVID-19 breakthrough infection.
2024cited by 0position: contributordoi
Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV
New England Journal of Medicine 2023cited by 55position: lastdoi
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana
Science Translational Medicine 2023cited by 42position: middledoi
Emulating Target Trials to Avoid Immortal Time Bias – An Application to Antibiotic Initiation and Preterm Delivery
Epidemiology 2023cited by 35position: middledoi
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana.
2023cited by 35position: contributordoi
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial
The Lancet HIV 2023cited by 27position: middledoi
Prevalence and control of hypertension in a high HIV-prevalence setting, insights from a population based study in Botswana
Scientific Reports 2023cited by 8position: lastdoi
No increased in utero and peripartum HIV acquisition risk in HIV-exposed preterm infants.
2023cited by 0position: contributordoi
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Nature 2022cited by 1,889position: middledoi
Iron, folic acid, and multiple micronutrient supplementation strategies during pregnancy and adverse birth outcomes in Botswana
The Lancet Global Health 2022cited by 42position: middledoi
Approaches to accelerating the study of new antiretrovirals in pregnancy.
2022cited by 17position: contributordoi
HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana.
2022cited by 16position: contributordoi
Doravirine-associated resistance mutations in antiretroviral therapy naïve and experienced adults with HIV-1 subtype C infection in Botswana
Journal of Global Antimicrobial Resistance 2022cited by 4position: contributordoi
Time for a Change: Optimizing Drug Data and Informed Choice in Pregnancy.
2022cited by 0position: contributordoi
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
The Lancet 2021cited by 157position: firstdoi
Maternal weight and birth outcomes among women on antiretroviral treatment from conception in a birth surveillance study in Botswana
Journal of the International AIDS Society 2021cited by 27position: middledoi
An assessment of a rapid SARS-CoV-2 antigen test in Bangladesh
2021cited by 0position: contributordoi
ASSESSMENT OF PERFORMANCE AND IMPLEMENTATION CHARACTERISTICS OF RAPID POINT OF CARE SARS-CoV-2 ANTIGEN TESTING
2021cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 19 papers (2019–2026)Roger Shapiro · Harvard University19 papers (2012–2026)Joseph Makhema · Beth Israel Deaconess Medical Center15 papers (2013–2026)Sikhulile Moyo · Weill Cornell Medicine11 papers (2013–2026) · 9 papers (2019–2026) · 8 papers (2019–2026) · 8 papers (2015–2023) · 6 papers (2018–2025)Joseph N Jarvis · University of London6 papers (2018–2025) · 6 papers (2017–2023)Scott Dryden‐Peterson · Harvard University5 papers (2012–2020)Ellen C. Caniglia · New York University5 papers (2020–2023) · 5 papers (2020–2023) · 5 papers (2018–2023) · 5 papers (2019–2026)Rebecca Zash · Harvard University5 papers (2020–2023) · 4 papers (2016–2024)Kathleen M. Powis · Lurie Children's Hospital4 papers (2012–2023)Max Essex · Harvard University4 papers (2012–2019)Judith S. Currier · MGH Institute of Health Professions4 papers (2012–2018)